DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: NaxRedy ™
Drug: Naloxone Hydrochloride Injection, USP

First Posted Date: 2022-03-03

Last Posted Date: 2022-03-03

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT05264493

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: PF-07321332/ritonavir

First Posted Date: 2022-03-03

Last Posted Date: 2024-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT05263921

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Phase 1

Active, not recruiting

Conditions: Breast Cancer
Solid Tumors

Interventions: Drug: PF-07220060 + PF-07104091 combination dose escalation
Drug: PF-07104091 + PF-07220060 + letrozole dose expansion
Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion

First Posted Date: 2022-03-02

Last Posted Date: 2024-11-18

Lead Sponsor: Pfizer

Target Recruit Count: 240

Registration Number: NCT05262400

Locations: 🇺🇸
Administrative Address: UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States

and more 46 locations

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Phase 1

Terminated

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinoma
Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma

Interventions: Drug: maplirpacept (PF-07901801)
Drug: Pegylated Liposomal Doxorubicin (PLD)

First Posted Date: 2022-03-02

Last Posted Date: 2024-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05261490

Locations: 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
🇺🇸
oncology Consultants, P.A., Houston, Texas, United States
🇺🇸
Oklahoma Cancer Specialist and Research Institute. LLC, Tulsa, Oklahoma, United States

and more 12 locations

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Phase 3

Recruiting

Conditions: COVID-19

Interventions: Drug: nirmatrelvir
Drug: ritonavir

First Posted Date: 2022-03-02

Last Posted Date: 2025-05-04

Lead Sponsor: Pfizer

Target Recruit Count: 160

Registration Number: NCT05261139

Locations: 🇧🇬
DCC "Alexandrovska", Sofia, Bulgaria
🇧🇬
Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria
🇲🇽
Fundación Santos y De la Garza Evia, Monterrey, Nuevo LEÓN, Mexico

and more 72 locations

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US

Completed

Conditions: Melanoma

Interventions: Drug: Encorafenib
Drug: Dabrafenib
Drug: Vemurafenib
Drug: Binimetinib
Drug: Cobimetinib
Drug: Trametinib

First Posted Date: 2022-03-02

Last Posted Date: 2025-03-06

Lead Sponsor: Pfizer

Target Recruit Count: 716

Registration Number: NCT05260684

Locations: 🇺🇸
Pfizer Investigational Site, New York, New York, United States

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders

Phase 3

Terminated

Conditions: Temporomandibular Disorders (TMD)

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2022-03-02

Last Posted Date: 2024-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 126

Registration Number: NCT05262517

Locations: 🇺🇸
The Medici Medical Research, LLC, Hollywood, Florida, United States
🇺🇸
The Medici Medical Research, Hollywood, Florida, United States
🇺🇸
Clinvest Research, LLC, Springfield, Missouri, United States

and more 29 locations

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1

Withdrawn

Conditions: Bladder Cancer

Interventions: Drug: PF-07225570
Drug: sasanlimab

First Posted Date: 2022-02-28

Last Posted Date: 2023-03-08

Lead Sponsor: Pfizer

Registration Number: NCT05259397

Locations: 🇵🇱
Szpital Specjalistyczny im. Sw. Rodziny SPZOZ, Warszawa, Poland
🇵🇱
Medical Concierge Centrum Medyczne, Warszawa, Poland
🇺🇸
Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States

and more 1 locations

A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Other: Placebo
Drug: IFN-β inhibitor treatment

First Posted Date: 2022-02-25

Last Posted Date: 2024-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT05257798

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Terminated

Conditions: Dermatitis, Atopic

First Posted Date: 2022-02-22

Last Posted Date: 2024-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 112

Registration Number: NCT05250115

Locations: 🇩🇪
Elbe Kliniken Stade - Buxtehude GmbH, Buxtehude, Niedersachsen, Germany
🇩🇪
ÜUeberoertliche Gemeinschaftspraxis Jost Kai Rietkoetter Robert Jablonka, Gelsenkirchen, Nordrhein-westfalen, Germany
🇩🇪
Dermatologische Gemeinschaftspraxis Dres. Quist PartG, Mainz, Rheinland-pfalz, Germany

and more 35 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy